机构:[1]Translational Medicine Collaborative Innovation Center, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), 518020, Shenzhen, China.深圳市人民医院深圳医学信息中心中国医科大学附属盛京医院中国医科大学盛京医院[2]Post-doctoral Scientific Research Station of Basic Medicine, Jinan University, 510632, Guangzhou, China.[3]Guangdong Engineering Technology Research Center of Stem Cell and Cell Therapy, Shenzhen Key Laboratory of Stem Cell Research and Clinical Transformation, Shenzhen Immune Cell Therapy Public Service Platform, 518020, Shenzhen, China.[4]Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 518172, Shenzhen, China.北京大学深圳医院深圳市康宁医院深圳市南山区人民医院深圳医学信息中心中国医学科学院肿瘤医院深圳医院[5]Deepxomics Co., Ltd, 518112, Shenzhen, China.[6]Experiment Center for Science and Technology, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.[7]Institute of Health Medicine, Southern University of Science and Technology, 518055, Shenzhen, China.
The present study was funded by the China Postdoctoral Science Foundation (2021M702290), Science and Technology Project of Shenzhen (No. GJHZ20170310090257380, JCYJ20170413092711058), Shenzhen Key Laboratory of Stem Cell Research and Clinical Transformation (ZDSYS20190902093203727), and National Natural Science Foundation of China (82001755).
第一作者机构:[1]Translational Medicine Collaborative Innovation Center, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), 518020, Shenzhen, China.[2]Post-doctoral Scientific Research Station of Basic Medicine, Jinan University, 510632, Guangzhou, China.[3]Guangdong Engineering Technology Research Center of Stem Cell and Cell Therapy, Shenzhen Key Laboratory of Stem Cell Research and Clinical Transformation, Shenzhen Immune Cell Therapy Public Service Platform, 518020, Shenzhen, China.
共同第一作者:
通讯作者:
通讯机构:[1]Translational Medicine Collaborative Innovation Center, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), 518020, Shenzhen, China.[3]Guangdong Engineering Technology Research Center of Stem Cell and Cell Therapy, Shenzhen Key Laboratory of Stem Cell Research and Clinical Transformation, Shenzhen Immune Cell Therapy Public Service Platform, 518020, Shenzhen, China.[7]Institute of Health Medicine, Southern University of Science and Technology, 518055, Shenzhen, China.
推荐引用方式(GB/T 7714):
Yan Hao-Jie,Lin Sheng-Cheng,Xu Shao-Hang,et al.Proteomic analysis reveals LRPAP1 as a key player in the micropapillary pattern metastasis of lung adenocarcinoma[J].HELIYON.2024,10(1):doi:10.1016/j.heliyon.2023.e23913.
APA:
Yan Hao-Jie,Lin Sheng-Cheng,Xu Shao-Hang,Gao Yu-Biao,Zhou Bao-Jin...&Li Fu-Rong.(2024).Proteomic analysis reveals LRPAP1 as a key player in the micropapillary pattern metastasis of lung adenocarcinoma.HELIYON,10,(1)
MLA:
Yan Hao-Jie,et al."Proteomic analysis reveals LRPAP1 as a key player in the micropapillary pattern metastasis of lung adenocarcinoma".HELIYON 10..1(2024)